In Medicines advisory bodies

Enter a keyword or phrase to search all pages in this section:


Advanced search

Archive:

Looking for a previously published document in this section?

British Pharmacopoeia Commission

The British Pharmacopoeia Commission (BPC) was established in 1970 under Section 4 of the Medicines Act 1968 to carry on the work of the previous Commission appointed by the General Medical Council (GMC). A Commission was first appointed by the GMC when the body was made statutorily responsible under the Medical Act of 1858 for producing a British Pharmacopoeia on a national basis.

Appointments to the British Pharmacopoeia Commission
The British Pharmacopoeia Commission is currently seeking to appoint two new members from 1 January 2008.

An advert has been placed on the website of the Appointments Commission (external link), which is the body responsible for carrying out the process. Interested parties will need to obtain an application form and information pack directly from them if they wish to apply. The post will also be advertised in the Pharmaceutical Journal on 8 September and should also be available via the New Scientist website.

Role
The British Pharmacopoeia Commission is responsible for preparing new editions of the British Pharmacopoeia and the British Pharmacopoeia (Veterinary) and for keeping them up-to-date. It also provides advice to the United Kingdom delegation to the European Pharmacopoeia Commission, of which the United Kingdom is a member. The BPC is also responsible, under Section 100 of the Medicines Act, for selecting and devising British Approved Names (BANs).

The Pharmacopoeia contributes to the overall control of the quality of medicinal products by providing an authoritative statement of the quality that a product is expected to meet at any time during its period of use. The publicly available and legally enforceable Pharmacopoeial standards are designed to complement and assist the licensing and inspection processes and are part of the system for safeguarding purchasers and users of medicinal products.

Provision of publicly available specification calls for a broad range of expertise and the BPC and its subsidiary committees include members from academia, hospitals, relevant industries and professional bodies.

Code of Practice
The Code of Practice below sets out the rules to be followed by chairmen and members of the British Pharmacopoeia Commission (BPC) holding and declaring interests in the pharmaceutical industry. The Code of Practice also provides guidance on holding and declaring other relevant interests, and on how interests that have been declared will be managed.
› Code of Practice for chairmen and members of the British Pharmacopoeia Commission

British Pharmacopoeia Commission Secretariat
The Secretariat of the British Pharmacopoeia Commission is part of the Inspection and Standards Division of the MHRA and the list of members is as follows:
Dr Ged Lee, Secretary and Scientific Director
Mrs Marine Cumberbatch, Personal Assistant to Dr Lee
Mrs Matilda Vallender, Editor-in-Chief
Mr Stephen Young, Head of Science
Dr Patience Holland, Principal Pharmacopoeial Scientist
Mr Richard L Turner, Principal Pharmacopoeial Scientist
Mrs Maria Barrett, Senior Pharmacopoeial Scientist
Mr Adrian Evans, Senior Pharmacopoeial Scientist
Dr Rosemary Pask-Hughes, Senior Pharmacopoeial Scientist
Dr Fiona Swanson, Senior Pharmacopoeial Scientist
Mr Alan Bentley, Higher Pharmacopoeial Scientist
Ms Nesta Thomas, Higher Pharmacopoeial Scientist
Ms Lorraine Phillips, Pharmacopoeial Administrator
Mr Brian Delahunty, Pharmacopoeial Support Officer
Mr Wayne Jeffries, Pharmacopoeial Support Officer

Contact for further information
For further information please contact British Pharmacopoeia, Market Towers, 1 Nine Elms Lane, Vauxhall, London SW8 5NQ,
telephone 020 7084 2561, fax 020 7084 2566 or e-mail bpcom@mhra.gsi.gov.uk

Latest documents for the British Pharmacopoeia Commission


Page last modified: 07 February 2008